Name | Number of supported studies | Average coverage | |
---|---|---|---|
macrophage | 6 studies | 23% ± 7% |
Insufficient scRNA-seq data for expression of AMDHD2 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
thymus | 100% | 1260.16 | 653 / 653 | 100% | 9.48 | 603 / 605 |
skin | 100% | 1240.16 | 1809 / 1809 | 100% | 22.19 | 470 / 472 |
prostate | 100% | 1074.93 | 245 / 245 | 99% | 10.96 | 499 / 502 |
esophagus | 100% | 911.94 | 1444 / 1445 | 99% | 5.44 | 182 / 183 |
uterus | 100% | 1081.87 | 170 / 170 | 99% | 9.62 | 456 / 459 |
adrenal gland | 100% | 1732.15 | 258 / 258 | 99% | 9.42 | 228 / 230 |
kidney | 100% | 1483.58 | 89 / 89 | 99% | 12.67 | 889 / 901 |
breast | 100% | 1280.11 | 459 / 459 | 98% | 11.03 | 1092 / 1118 |
liver | 98% | 622.04 | 222 / 226 | 99% | 10.25 | 403 / 406 |
bladder | 100% | 959.43 | 21 / 21 | 97% | 8.54 | 491 / 504 |
intestine | 100% | 1223.24 | 966 / 966 | 97% | 7.26 | 512 / 527 |
lung | 99% | 1216.57 | 575 / 578 | 97% | 7.08 | 1126 / 1155 |
ovary | 99% | 900.96 | 179 / 180 | 97% | 5.86 | 419 / 430 |
brain | 97% | 687.38 | 2551 / 2642 | 100% | 8.97 | 704 / 705 |
stomach | 100% | 729.19 | 358 / 359 | 95% | 6.58 | 271 / 286 |
pancreas | 94% | 436.72 | 309 / 328 | 99% | 8.78 | 177 / 178 |
adipose | 100% | 1239.96 | 1204 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 39.43 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 20.93 | 29 / 29 |
spleen | 100% | 2282.48 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 8.73 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 7.08 | 1 / 1 |
blood vessel | 100% | 861.53 | 1331 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 99% | 1127.30 | 916 / 929 | 0% | 0 | 0 / 0 |
heart | 93% | 420.01 | 802 / 861 | 0% | 0 | 0 / 0 |
muscle | 93% | 424.39 | 744 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006046 | Biological process | N-acetylglucosamine catabolic process |
GO_0006048 | Biological process | UDP-N-acetylglucosamine biosynthetic process |
GO_0019262 | Biological process | N-acetylneuraminate catabolic process |
GO_0005829 | Cellular component | cytosol |
GO_0005634 | Cellular component | nucleus |
GO_0008448 | Molecular function | N-acetylglucosamine-6-phosphate deacetylase activity |
GO_0047419 | Molecular function | N-acetylgalactosamine-6-phosphate deacetylase activity |
GO_0005515 | Molecular function | protein binding |
GO_0046872 | Molecular function | metal ion binding |
Gene name | AMDHD2 |
Protein name | N-acetylglucosamine-6-phosphate deacetylase (GlcNAc 6-P deacetylase) (EC 3.5.1.25) (Amidohydrolase domain-containing protein 2) N-acetylglucosamine-6-phosphate deacetylase (EC 3.5.1.25) Amidohydrolase domain containing 2 |
Synonyms | CGI-14 |
Description | FUNCTION: Hydrolyzes the N-glycolyl group from N-glycolylglucosamine 6-phosphate (GlcNGc-6-P) in the N-glycolylneuraminic acid (Neu5Gc) degradation pathway. Although human is not able to catalyze formation of Neu5Gc due to the inactive CMAHP enzyme, Neu5Gc is present in food and must be degraded. . FUNCTION: Hydrolyzes the N-glycolyl group from N-glycolylglucosamine 6-phosphate (GlcNGc-6-P) in the N-glycolylneuraminic acid (Neu5Gc) degradation pathway. . |
Accessions | ENST00000568263.5 A0A3B3IU33 ENST00000302956.8 [Q9Y303-2] ENST00000413459.7 [Q9Y303-3] H3BT49 ENST00000293971.11 [Q9Y303-1] Q9Y303 ENST00000648227.1 H3BSD5 ENST00000563556.1 H3BTE3 H3BTZ6 ENST00000569879.5 ENST00000563633.5 H3BSV9 ENST00000566706.5 |